desktop version →
Language & Currency
Shopping cart: 0 items $0.00
Free Shipping
on all orders above $200
Free Pills
with every order
1,000,000 customers
quality, privacy, secure
Low prices
best price on the web


Nolvadex (Tamoxifen) is used for treating breast cancer in women.
Active Ingredient: tamoxifen
Availability: In Stock (36 Packages)
Save your money
Mega Discounts on Big Packs
Nolvadex 20mg
Product namePer PillSavings (only today)Per Pack
30 pills$1.21$36.34ADD TO CART
60 pills$0.85$21.41$72.68 $51.27ADD TO CART
90 pills$0.74$42.81$109.01 $66.20ADD TO CART
120 pills$0.68$64.22$145.35 $81.13ADD TO CART
180 pills$0.62$107.03$218.03 $111.00ADD TO CART
270 pills$0.58$171.25$327.04 $155.79ADD TO CART
360 pills$0.56$235.47$436.05 $200.58ADD TO CART
Nolvadex 10mg
Product namePer PillSavings (only today)Per Pack
60 pills$0.91$54.42ADD TO CART
90 pills$0.75$14.04$81.63 $67.59ADD TO CART
120 pills$0.67$28.08$108.84 $80.76ADD TO CART
180 pills$0.60$56.17$163.28 $107.11ADD TO CART
270 pills$0.54$98.29$244.91 $146.62ADD TO CART
360 pills$0.52$140.41$326.54 $186.13ADD TO CART
  • Nolvadex - a treating and preventing remedy for breast cancer

    Nolvadex drug has been firstly designed in 60’s. Its primary indication consisted in the treatment of female infertility. Later on, the medication has been more profoundly studied in cancer field, where its pharmacological properties have gained significant value in the treatment of breast cancer. Nolvadex is pharmacologically categorized as a Selective Estrogen Receptor Modulator. In simplistic terms, this would mean that it blocks the action of naturally-occurring estrogen at receptor sites namely in breast tissue, by occupying the receptors where natural estrogen should normally be placed on. As a result, natural estrogen cannot bind to its receptors and does not exert its physiologic properties. Thus, in lately 70’s, Nolvadex has been officially approved for the treatment of breast cancer in both men and women, while in late 80’s it has been recognized as a preventive aid for the same condition. 

    Nowadays, Nolvadex is prescribed particularly for estrogen-responsive breast cancer. “Estrogen-responsive cancer” refers to malignancy that develops as a result of estrogen activity within the body. Since Nolvadex is expected to disrupt naturally-occurring estrogen activity, breast malignancy is expected to shrink. 

    As what refers to prophylactic use of Nolvadex, it is given to patients who are at increased risk of developing breast cancer. Patients “at increased risk” should refer to persons with genetic predisposition of breast cancer or breast biopsy indicating atypical hyperplasia. 

    Description of Nolvadex drug

    Nolvadex is commercialized in tablets for oral administration. These are released in 10 and 20 mg strength. Following inactive ingredients, with no pharmacological value, are added: mannitol, carboxymethylcellulose calcium, starch and magnesium stearate. The basic compound exhibiting anti-estrogen activity is tamoxifen citrate, chemically designed as follows: C32H37NO8. This compound is effective in both men and women. It can be given to pre and postmenopausal females. Following benefits are gained with this chemical: reduces the risk of recurrent breast cancer following surgery, shrinks advanced breast cancer before surgery, treats metastatic hormone-receptor-positive breast cancer, as well as prevents breast cancer development in patients at higher-than-average risk. 

    Restrictions for Nolvadex use

    Nolvadex must not be taken by patients with known hypersensitivity to tamoxifen citrate. All complementary compounds should be taken into consideration when evaluating the allergenic profile of each patient.

    Active or previous deep vein thrombosis is a contraindication for Nolvadex use. 

    Risks associated with Nolvadex therapy

    Uterine sarcoma and endometrial adenocarcinoma are highly likely with Nolvadex therapy. The incidence of such outcomes varies from 2-4%. The necessity of Nolvadex therapy should be judiciously decided in patients with increased risk of breast cancer. All benefits against mentioned risks should be carefully examined and the drug shall be instituted exclusively in cases of higher-than-average risk of breast malignancy development. The recommendation is not appropriate for patients with confirmed breast cancer diagnosis. In such settings, the need for Nolvadex therapy justifies the potential hazard. 

    Estrogenic properties of Nolvadex can give rise to endometrial hyperplasia and polyps. Close monitoring for such complications is required. 

    Nolvadex is closely related to thromboembolic events in patients with or without thromboembolic history. 

mobile version →